
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37581323
CN-22-904
10.2174/1570159X21666230811141557
Medicine, Neurology, Pharmacology, Neuroscience
The HPA Axis as Target for Depression
Menke Andreas 12*
1 Department of Psychosomatic Medicine and Psychotherapy, Medical Park Chiemseeblick, Rasthausstr, 25, 83233 Bernau am Chiemsee, Germany;
2 Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany
* Address correspondence to this author at the Department of Psychosomatic Medicine and Psychotherapy, Medical Park Chiemseeblick, Rasthausstr. 25, 83233 Bernau am Chiemsee, Germany; and Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany; E-mail: a.menke@medicalpark.de
24 8 2023
2024
22 5 904915
16 11 2022
30 12 2022
04 1 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Major depressive disorder (MDD) is a stress-related mental disorder with a lifetime prevalence of 20% and, thus, is one of the most prevalent mental health disorders worldwide. Many studies with a large number of patients support the notion that abnormalities of the hypothalamus-pituitary-adrenal (HPA) axis are crucial for the development of MDD. Therefore, a number of strategies and drugs have been investigated to target different components of the HPA axis: 1) corticotrophin-releasing hormone (CRH) 1 receptor antagonists; 2) vasopressin V1B receptor antagonists, 3) glucocorticoid receptor antagonists, and 4) FKBP5 antagonists. Until now, V1B receptor antagonists and GR antagonists have provided the most promising results. Preclinical data also support antagonists of FKBP5, which seem to be partly responsible for the effects exerted by ketamine. However, as HPA axis alterations occur only in a subset of patients, specific treatment approaches that target only single components of the HPA axis will be effective only in this subset of patients. Companion tests that measure the function of the HPA axis and identify patients with an impaired HPA axis, such as the dexamethasone-corticotrophin-releasing hormone (dex-CRH) test or the molecular dexamethasone-suppression (mDST) test, may match the patient with an effective treatment to enable patient-tailored treatments in terms of a precision medicine approach.

Keywords

HPA axis
precision medicine
biomarkers
stress
depression
antidepressants
vasopressin
V1B receptor antagonist
SSR149415
FKBP5
CRH1
glucocorticoid receptor
==== Body
pmc1 INTRODUCTION

Major depressive disorder (MDD) is a widespread disease with a lifetime prevalence of around 20% [1]. The Global Burden of Disease study estimated that MDD is one of the three most disabling conditions worldwide [2, 3], and according to the World Health Organization, MDD will be the leading cause of disease burden worldwide by 2030 [4]. MDD is a disorder with heterogenous symptoms that substantially compromise social and occupational functioning, and is associated with an increased risk for premature death and suicidality. Patients with MDD have a twofold increased mortality and a reduced life expectancy of 7-14 years [5, 6]. This excess mortality is not only due to suicide, but is also explained by the onset or worsening of somatic disorders, such as heart disease, metabolic syndrome, diabetes mellitus, cancer, or stroke [7]. Although numerous effective antidepressants exist, more than 50% of patients fail to respond to the first antidepressant they are prescribed [8], and about 30% do not respond even after several treatment attempts [9]. These cases are often grouped under the term treatment-resistant depression (TRD), which is mostly defined as an MDD that persists after two adequate trials with antidepressants [10]. In addition to the high rates of partial or no response, the commonly used antidepressants have a delayed onset of treatment effects and uncomfortable or even threatening adverse side effects [11]. Disturbing findings show that even remitted patients still suffer from a functional impairment [12]. These non-sufficient treatment options lead to high rates of early retirement and sick leave [13]. Several factors account for this situation, like MDD is a heterogenous disorder with poorly defined subgroups or endophenotypes, and most of the currently available antidepressants have similar mechanisms with targeting components of the serotonin, norepinephrine, and dopamine signaling [14]. Additionally, there are no genetic markers or biomarkers that reliably match patients with effective treatment options [14-16]. Just recently, the glutamatergic modulator ketamine was discovered as a new treatment option for MDD, which exerts antidepressant effects in minutes to hours that persist long after drug excretion [17]. This discovery led to the approval of a nasal spray form of esketamine that is supposed to provide relief in patients with TRD [18]. With the advent of these noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists, the spectrum of available antidepressants was expanded. However, there is still the need for objective, measurable biomarkers to enable a precision medicine approach to match the patient with the treatment, providing the best possible response and minimal adverse effects.

2 MDD, CHILDHOOD TRAUMA, AND THE HPA AXIS

Until now, no established mechanism can explain all aspects of MDD [11]. There is a robust heritability of around 40% [19]. However, the development of MDD also substantially depends on gene x environmental interactions [20-22]. Early-life stress, such as physical, sexual, or emotional childhood trauma, has been generally associated with MDD [23, 24], but the increase of MDD risk is also moderated by genetic variants, for example, by FKBP5 variants [25], encoding the FK 506 binding protein 51 or FKBP51, a co-chaperone of the heat-shock protein 90 (hsp90) [26]. FKBP5 is a crucial moderator of the hypothalamic-pituitary-adrenal (HPA) axis function, which is responsible for the fight-or-flight response [27]. The HPA axis is substantially shaped by childhood trauma. In fact, childhood trauma may lead to an increase in HPA axis sensitivity and, thus, to a heightened response to subsequent stressors [28, 29]. In addition to early-life stress, aversive stressful events later in life increase the risk of developing MDD. Aversive events, such as loss of employment, financial insecurity, life-threatening or chronic health problems, bereavement, and separation, often occur in the year preceding the MDD onset [30]. Both early-life stress and stressful events later in life compromise the treatment response to antidepressants in patients with MDD, possibly by impairing the function of the HPA axis [31, 32]. Alterations in the HPA axis are robustly found in MDD [33, 34], mostly in terms of HPA axis hyperactivity due to an impaired sensitivity to negative feedback regulation [35, 36].

3 THE HPA AXIS

Environmental stress leads to the release of monoamines, norepinephrine, serotonin, and dopamine from the hippocampus, amygdala, and other brain regions. Subsequently, the corticotrophin-releasing hormone (CRH) is released by the paraventricular nucleus (PVN) of the hypothalamus. CRH binds to the corticotrophin-releasing hormone 1 (CRH1) and CRH2 receptors in the anterior pituitary, and activates the secretion of adrenocorticotropic hormone (ACTH) into the systemic circulation [37, 38]. Arginine-vasopressin (AVP), another hypothalamic peptide, is produced in the PVN and the supraoptic nucleus, and then released from the median eminence in the posterior pituitary or into the hypophyseal portal system, like CRH [39, 40]. In addition, preclinical evidence supports the notion that retinoid family members, including vitamin A, may not only influence brain development but also the function of the HPA axis [41]. AVP supports ACTH secretion in combination with CRH, which seems to be of interest in states of chronic stress [42]. ACTH activates the synthesis and secretion of glucocorticoids (GC, e.g., cortisol) in the adrenal cortex. AVP is also synthesized locally in the adrenal medulla and activates the release of cortisol. Cortisol exerts its effects via two distinct mechanisms: intracellular glucocorticoid receptors (GR) translocate to the cell nucleus to regulate gene expression and membrane-bound GR that induce rapid protein kinase signaling [43, 44]. In addition to the GR, mineralocorticoid receptors (MR) bind cortisol [45]. The GR has a lower affinity for cortisol than the MR and, thus, can better identify high cortisol concentrations that occur during a response to stress. To reinstate homeostasis after stress response, negative feedback mechanisms are activated; cortisol binds to GR of the pituitary, the hippocampus, and the PVN, and inhibits the further release of CRH [43, 44]. The sensibility of these negative feedback mechanisms, mainly the GR sensitivity, is substantially regulated by FKBP5, which provides an ultra-short feedback loop for GR sensitivity. GR activation induces FKBP5 mRNA and FKBP51 protein expression, then FKBP51 is bound to the GR complex, glucocorticoid-binding affinity is reduced, and the GR translocates into the cell nucleus less efficiently [26]. The regulation of these negative feedback loops is crucial for an adaptive stress response [46].

4 MEASURING THE HPA AXIS ACTIVITY

Several tests have been developed to identify malfunctions of the HPA axis [47]. The first test to detect HPA axis alterations was the dexamethasone suppression test (DST), which identifies an insufficient suppression of cortisol following dexamethasone intake [48]. An insufficient cortisol suppression was repeatedly found in patients suffering from MDD [49-51]. However, the DST achieved only a modest sensitivity between 20 and 50% to detect MDD [52, 53], and thus is not employed in standard clinical care [51, 54, 55]. To improve the sensitivity and the specificity, the DST was combined with a CRH stimulation, the dexamethasone-corticotropin-releasing hormone (dex-CRH) test. Usually, dexamethasone was ingested at 11 pm; the next day, CRH was injected at 3 pm, and cortisol was measured before and several times after CRH injection [56, 57]. In fact, sensitivity to identify alterations of the HPA axis could be increased with a successful classification of depressed patients up to 80% [56, 57]. Several studies could replicate these findings [58-60]; however, others could not [52, 53]. In addition, studies have suggested that the dex-CRH test may allow the classification of subgroups and predict treatment response and disease course. For example, an early normalization of the cortisol response in the dex-CRH test has been associated with a response to antidepressants [60]. An increased cortisol response to the dex-CRH test in patients at remission predicted an increased risk of relapse [60-62] as well as a higher risk of suicide attempt or suicide completion [63, 64]. However, we recently observed that the readouts of the dex-CRH test are substantially dependent on the plasma concentrations; therefore, the factors that influence the plasma concentrations do also influence the readout of the dex-CRH test [65]. Overall, findings seem to be heterogenous and effect sizes modest; however, a meta-analysis including over 18,000 individuals observed greater effect sizes and cortisol alterations in depressed patients when the HPA axis was artificially challenged compared to when it was not [34]. Recently, we have developed a modified molecular genetic version of the DST, mDST [47, 66]. After blood sampling at 6 pm, dexamethasone was administered, and three hours later, blood was sampled again for measurement of cortisol, ACTH, differential blood count, and gene expression signatures [47, 67, 68]. The mDST was able to identify HPA axis alterations in MDD [67], job-related exhaustion [69], anxious depression and childhood trauma [70], chronic stress [31], and healthy females compared to healthy men [71]. Of note, the results of the mDST were not dependent on dexamethasone plasma concentration [65]. Using the mDST in a broader approach with stimulated expression quantitative trait locus (eQTL), we combined the gene expression signatures after dexamethasone stimulation with genome-wide single nucleotide polymorphism (SNP) data and found that common genetic variants that modulate the transcriptional response to GR-activation influence the risk to develop MDD and other mental disorders [72]. In addition, we found that the methylation status of the FKBP5 locus moderated the dynamic changes following GR activation, and was associated with early and current life stress [73].

5 SPECIFIC TARGETS OF THE HPA AXIS

A wealth of data report hyperactivity of the HPA axis with impaired sensitivity to negative feedback regulation in MDD [36, 74, 75], particularly in MDD with psychotic features [38, 76, 77]. A number of strategies have been investigated to normalize an altered HPA axis function and treat MDD (Fig. 1) [15, 78]. A recent meta-analysis of over 16 randomized controlled trials (RCT) and 7 open-label trials with 2972 subjects exploring medications that target the HPA axis observed a significant difference in the efficacy across all medications between interventions and controls [79]. The analysis of subgroups resulted in a significant difference favoring the GR antagonist mifepristone and vasopressin 1B (V1B) receptor antagonists [79].

6 VASOPRESSIN V1B RECEPTOR ANTAGONISTS

AVP and its receptor subtype, V1B, play a pivotal role in HPA axis regulation. AVP is produced in the PVN and supraoptic nucleus of the hypothalamus and released into the pituitary portal circulation to potentiate the effects of CRH on ACTH release [80]. AVP exerts its effects through 3 G-protein coupled receptor subtypes, V1A, V1B, and V2 [81], while V1B is expressed in the majority of ACTH-secreting cells in the anterior pituitary and, thus, regulates the HPA axis activity by AVP [80]. Chronic stress increases AVP-containing neurons in the PVN [82] and increases V1B receptor expression in the pituitary [82]. Studies have found increased AVP concentrations in plasma and in brain regions, such as PVN, the supraoptic nucleus, and the suprachiasmatic nucleus of patients suffering from MDD [83]. These findings indicate that AVP is activated in conditions, like chronic stress and MDD. Meanwhile, several pharmaceutical companies have discovered and developed nonpeptidergic V1B receptor antagonists that are safe, tolerable, and penetrate the blood-brain-barrier [84, 85]. Clinical trials have been conducted with 3 different V1B receptor antagonists for the treatment of MDD: the compound with the largest clinical database Sanofi's SSR149415/nelivaptan [86], AbbVie’s ABT-436 [87], and Taisho Pharmaceutical’s TS-121 [88]. SSR149415 led with a dosage of 250 mg, not with 100 mg, to a significantly greater reduction in the Hamilton Depression Rating Scale (HDRS) after 8 weeks; however, the trial failed because the comparator escitalopram did not achieve a significant reduction in the HDRS. Another trial with 100 mg and 250 mg SSR149415 did not show a significant improvement compared to placebo. Interestingly, SSR149415 with dosage up to 250 mg did not reduce the cortisol response to the CRH challenge, while doses higher than 250 mg significantly reduced the cortisol response. Thus, the administered doses of SSR149415 in the failed trials may have been too low to affect HPA axis function and improve depressive symptoms. The ABT-436 compound showed some favorable effects on 2 of 5 Mood and Anxiety Questionnaire (MASQ) subscales; however, no significant effect on the HDRS was found. The third compound, TS-121, provided a larger reduction in the Montgomery-Asberg Depression Rating Scale (MADRS) score than the placebo after 6 weeks; however, this effect was not statistically significant. It can be assumed that not all depressed patients display alterations in HPA axis function or AVP-V1B signaling; therefore, a drug targeting only these components would have no effect in patients with normal AVP-V1B signaling and fail to reduce depressive symptoms. Thus, a companion test would be needed to identify the patients who would benefit from these compounds, such as the dex-CRH test or the modified molecular mDST [15, 36, 47, 67, 84].

7 GR ANTAGONISTS

Most studies have been conducted on MDD with psychotic features, as this subgroup displays pronounced hypercortisolism and impaired negative feedback loops. Mifepristone, which blocks both the GR and the progesterone receptors, is the most tested GR antagonist [78, 79]. Most of the mifepristone trials have been found to be much shorter than the usual trials; the participants have received mifepristone for 4-8 days, and the depressive symptoms were assessed 1 week later, 1 month later, and even later, when patients received only standard antidepressant monotherapy. 4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials. Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo. Interestingly, it was observed that the effectiveness of mifepristone could be optimized when plasma concentrations of about 1600 ng/ml were reached, which equates to around 1200 mg/day [95]. These results may explain why other trials have failed to show significant improvements. In fact, a recent combined analysis of the data from five placebo-controlled trials with cases n = 833 and placebo n = 627 observed patients to gain a significant reduction in psychotic symptoms if they had plasma concentrations within the therapeutic range [96]. Overall, mifepristone may be an individualized treatment option for patients with MDD involving psychotic features.

8 CRH1 RECEPTOR ANTAGONISTS

Preclinical and clinical evidence clearly supports the CRH excess production in the development of MDD [35, 97, 98]. In preclinical models, behavioral effects that resemble the symptoms of depression and anxiety could be provoked by central injection of CRH [99, 100]. These behavioral manifestations could be attenuated by central injection of specific CRH receptor antagonists [99]. In addition, clinical studies observed CRH hyperactivity in patients with depression and anxiety [99]. A clinical trial that investigated the CRH1 receptor antagonist R121919 revealed a significant reduction in the HRDS in patients with MDD [101]. However, R121919 was withdrawn because of liver enzyme elevations. Another CRH1 receptor antagonist, CP-316,311, could not achieve a significant improvement of depressive symptoms compared to placebo [102]. Additional trials that administered CRH1 receptor antagonists in patients with MDD and anxiety disorders also failed to improve depressive or anxious symptoms [103]. A study that investigated the CRH1 receptor antagonist GSK561679/Verucerfont attenuated the response of the HPA axis to social stressors and the amygdala response to negative affective stimuli in anxious, alcohol-dependent women [104]. The same compound was further investigated in a double-blind, randomized and placebo-controlled trial with women suffering from post-traumatic stress disorder (PTSD) [105, 106]. While this trial could not reveal a significant improvement of PTSD symptoms, patients with a history of childhood trauma and a certain CRH1 receptor single nucleotide polymorphism (SNP) genotype did only respond to Verucerfont, and not to placebo [106]. These findings again support the notion that drugs with very narrow specific mechanisms are only effective in patients with corresponding pathophysiology and that a matching of patients with treatment options using biomarkers or genetic markers is necessary [14].

9 FKBP5 ANTAGONISTS AND KETAMINE

After the discovery of FKBP51 as a major stress regulator and its association with depression recurrence and response to antidepressant treatment [107], it has been extensively studied [108]. Numerous clinical and preclinical studies have robustly observed FKBP5/FKBP51 to be a central mediator of childhood adversity and HPA axis dysfunction and other sequelae [108-110]. In addition, FKBP5 was associated with MDD [111], bipolar disorder [112], schizophrenia [113], posttraumatic stress disorder [114, 115], attention deficit hyperactivity disorder (ADHD) [116], chronic pain [117, 118] and metabolic dysfunction, insulin resistance and obesity [119, 120]. A wealth of data from genetic, epigenetic, and postmortem data support the fact that increased FKBP5 expression is associated with the risk of mental disorders, and the manipulation of FKBP5 in preclinical studies leads to the normalization of impaired behavior [108]. Recently, an increased FKBP5 mRNA expression was associated with HPA axis dysfunction and worse response to antidepressants in patients suffering from MDD [121]. Therefore, FKBP5 antagonism, at least for certain patient groups, may be a suitable treatment approach [108]. Several preclinical studies with models of depression or anxiety have consistently observed protective effects of FKBP5 knock-out or knock-down on HPA axis function or stress-coping behavior [122]. The drug discovery was difficult because all known ligands could not differentiate between FKPB51 and the opposing homolog FKBP52 [123, 124]. The development of FKBP51 ligands led to SAFit (Selective Antagonists of FKPB51 by induced fit); SAFit1 and SAFit2 were found to be highly selective inhibitors of FKBP51. They achieved selectivity by an induced fit mechanism [125, 126]. SAFit1 and SAFit2 achieved an improvement in stress-coping behavior and neuroendocrine feedback in preclinical models [125, 126]. In addition, SAFit1 and SAFit2 could also improve metabolic function and glucose homeostasis [127]. Just recently, the first macrocyclic FKBP51-selective ligands to stabilize the active conformation were designed and synthesized [128]. The effects of FKBP51 could also be influenced by manipulating the mineralocorticoid receptor (MR); pharmacological inhibition of MR produced a decrease in FKBP51 and dampened the stress-induced increase in glucocorticoids [129]. Recently, a new class of fast-acting antidepressants has emerged. Numerous evidences link glutamatergic alterations to the development of MDD [130, 131]. The glutamatergic modulator ketamine has been extensively studied for two decades and robust antidepressive effects have been documented that occur in a matter of minutes after administration and persist long after drug excretion [132]. While there are two active enantiomers of ketamine, R-ketamine and S-ketamine, with both exerting antidepressive effects [133, 134], a nasal spray form of S-ketamine was approved by the Food and Drug Administration (FDA) in the USA and by the European Medicines Agency (EMA) in Europe in 2019 [18]. Ketamine and its enantiomers do not only antagonize the N-methyl-D-aspartate (NMDA) receptors, but also induce rapid brain-derived neurotrophic factor (BDNF) translation and release in brain areas, which is supposed to be responsible for neuroplastic effects [17]. Interestingly, the S-ketamine-evoked mature mBDNF secretion is strongly dependent on the expression of FKBP51, and in FKBP51 know-out mice, the S-ketamine-induced antidepressive effects were blunted [135]. Similar effects were observed in stress-coping models in mice, where FKBP51 was required for stress-coping induced by paroxetine and amitriptyline [136]. In addition, an altered expression of the HPA axis-modulating components, FKBP51 and SGK1 [137, 138], was observed following ketamine administration [139].

CONCLUSION

Alterations of the HPA axis in MDD are robustly documented. However, not all of the patients with MDD display a dysfunction of the HPA axis [34]. Even if the patients do have an impaired function of the HPA axis, the malfunction may occur on different levels of the HPA axis signaling cascade. This may be the reason why specific compounds that target the HPA axis at very specific sites, such as V1B receptor antagonists, CRH1 receptor antagonists or GR antagonists, improve depressive symptoms only in a certain proportion of the patients. To match the patient with the right treatment approach in terms of an individualized treatment, it is necessary to apply tests that assess the function of the HPA axis, such as the dex-CRH test or the molecular DST [14, 47]. This approach would identify suitable patients for specific HPA axis-targeting drugs. Meanwhile, several drugs with different treatment strategies have achieved beneficial effects in MDD. These drugs did not only improve depressive symptoms, but also ameliorated the impairments of the HPA axis, and were generally well tolerated. Especially the V1B receptor antagonists, such as SSR149415/Nelivaptan, and the GR antagonist, mifepristone, delivered promising results [79]. But also, FKBP51 antagonists, which were not yet tested in clinical samples, achieved very interesting findings in preclinical models of depression and anxiety; in addition, FKBP51 seems to be necessary for some effects exerted by ketamine [135].

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

ADHD Attention Deficit Hyperactivity Disorder

AVP Arginine-vasopressin

CRH Corticotrophin-releasing Hormone

DST Dexamethasone Suppression Test

GR Glucocorticoid Receptors

HDRS Hamilton Depression Rating Scale

HPA Hypothalamic-pituitary-adrenal

MDD Major Depressive Disorder

MR Mineralocorticoid Receptors

NMDA N-methyl-D-aspartate

PTSD Post-traumatic Stress Disorder

PVN Paraventricular Nucleus

SNP Single Nucleotide Polymorphism

TRD Treatment-resistant Depression

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The author acknowledges the health insurance company, AOK, the Bavarian General Practitioner’s Association, Medice and Neuraxpharm.

Fig. (1) The hypothalamus-pituitary-adrenal (HPA) axis: The corticotrophin-releasing hormone (CRH) is released by the paraventricular nucleus (PVN) of the hypothalamus and then binds to the corticotrophin-releasing hormone 1 CRH1 receptors in the anterior pituitary (target 1). The secretion of adrenocorticotropic hormone (ACTH) into the peripheral circulation is activated. In addition, arginine-vasopressin (AVP) is also produced in the PVN and released into the pituitary circulation, where it potentiates the effects of CRH on ACTH release via activation of V1B receptors (target 2). ACTH induces the release of cortisol in the adrenal cortex, which exerts its effects on peripheral cells. Cortisol also activates the negative feedback loops by stimulating the glucocorticoid receptors (GR) in the pituitary and the hypothalamus to reinstate homeostasis (target 3). The GR complex consists of the co-chaperones FKBP51 and FKBP52 of the heat-shock protein hsp90 dimer and the co-chaperone molecule p23. When FKBP51 is bound to the receptor complex, cortisol binds with lower affinity (target 4). After cortisol binding, FKBP51 is exchanged against FKBP52, and nuclear translocation and transcriptional activity are enabled. In terms of an ultrashort negative feedback loop, GR activation leads to transcription and translation of FKBP51, which reduces GR sensitivity. Reprinted from Psychoneuroendocrinology, Volume 91, Carolin Leistner, Andreas Menke, How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders, 235-260, Copyright (2018), with permission from Elsevier.
==== Refs
REFERENCES

1 Ebmeier K.P. Donaghey C. Steele J.D. Recent developments and current controversies in depression. Lancet 2006 367 9505 153 167 10.1016/S0140-6736(06)67964-6 16413879
2 Vos T. Barber R.M. Bell B. Bertozzi-Villa A. Biryukov S. Bolliger I. Charlson F. Davis A. Degenhardt L. Dicker D. Duan L. Erskine H. Feigin V.L. Ferrari A.J. Fitzmaurice C. Fleming T. Graetz N. Guinovart C. Haagsma J. Hansen G.M. Hanson S.W. Heuton K.R. Higashi H. Kassebaum N. Kyu H. Laurie E. Liang X. Lofgren K. Lozano R. MacIntyre M.F. Moradi-Lakeh M. Naghavi M. Nguyen G. Odell S. Ortblad K. Roberts D.A. Roth G.A. Sandar L. Serina P.T. Stanaway J.D. Steiner C. Thomas B. Vollset S.E. Whiteford H. Wolock T.M. Ye P. Zhou M. Ãvila M.A. Aasvang G.M. Abbafati C. Ozgoren A.A. Abd-Allah F. Aziz M.I.A. Abera S.F. Aboyans V. Abraham J.P. Abraham B. Abubakar I. Abu-Raddad L.J. Abu-Rmeileh N.M.E. Aburto T.C. Achoki T. Ackerman I.N. Adelekan A. Ademi Z. Adou A.K. Adsuar J.C. Arnlov J. Agardh E.E. Al Khabouri M.J. Alam S.S. Alasfoor D. Albittar M.I. Alegretti M.A. Aleman A.V. Alemu Z.A. Alfonso-Cristancho R. Alhabib S. Ali R. Alla F. Allebeck P. Allen P.J. AlMazroa M.A.A. Alsharif U. Alvarez E. Alvis-Guzman N. Ameli O. Amini H. Ammar W. Anderson B.O. Anderson H.R. Antonio C.A.T. Anwari P. Apfel H. Arsenijevic V.S.A. Artaman A. Asghar R.J. Assadi R. Atkins L.S. Atkinson C. Badawi A. Bahit M.C. Bakfalouni T. Balakrishnan K. Balalla S. Banerjee A. Barker-Collo S.L. Barquera S. Barregard L. Barrero L.H. Basu S. Basu A. Baxter A. Beardsley J. Bedi N. Beghi E. Bekele T. Bell M.L. Benjet C. Bennett D.A. Bensenor I.M. Benzian H. Bernabe E. Beyene T.J. Bhala N. Bhalla A. Bhutta Z. Bienhoff K. Bikbov B. Abdulhak A.B. Blore J.D. Blyth F.M. Bohensky M.A. Basara B.B. Borges G. Bornstein N.M. Bose D. Boufous S. Bourne R.R. Boyers L.N. Brainin M. Brauer M. Brayne C.E.G. Brazinova A. Breitborde N.J.K. Brenner H. Briggs A.D.M. Brooks P.M. Brown J. Brugha T.S. Buchbinder R. Buckle G.C. Bukhman G. Bulloch A.G. Burch M. Burnett R. Cardenas R. Cabral N.L. Nonato I.R.C. Campuzano J.C. Carapetis J.R. Carpenter D.O. Caso V. Castaneda-Orjuela C.A. Catala-Lopez F. Chadha V.K. Chang J-C. Chen H. Chen W. Chiang P.P. Chimed-Ochir O. Chowdhury R. Christensen H. Christophi C.A. Chugh S.S. Cirillo M. Coggeshall M. Cohen A. Colistro V. Colquhoun S.M. Contreras A.G. Cooper L.T. Cooper C. Cooperrider K. Coresh J. Cortinovis M. Criqui M.H. Crump J.A. Cuevas-Nasu L. Dandona R. Dandona L. Dansereau E. Dantes H.G. Dargan P.I. Davey G. Davitoiu D.V. Dayama A. De la Cruz-Gongora V. de la Vega S.F. De Leo D. del Pozo-Cruz B. Dellavalle R.P. Deribe K. Derrett S. Des Jarlais D.C. Dessalegn M. deVeber G.A. Dharmaratne S.D. Diaz-Torne C. Ding E.L. Dokova K. Dorsey E.R. Driscoll T.R. Duber H. Durrani A.M. Edmond K.M. Ellenbogen R.G. Endres M. Ermakov S.P. Eshrati B. Esteghamati A. Estep K. Fahimi S. Farzadfar F. Fay D.F.J. Felson D.T. Fereshtehnejad S-M. Fernandes J.G. Ferri C.P. Flaxman A. Foigt N. Foreman K.J. Fowkes F.G.R. Franklin R.C. Furst T. Futran N.D. Gabbe B.J. Gankpe F.G. Garcia-Guerra F.A. Geleijnse J.M. Gessner B.D. Gibney K.B. Gillum R.F. Ginawi I.A. Giroud M. Giussani G. Goenka S. Goginashvili K. Gona P. de Cosio T.G. Gosselin R.A. Gotay C.C. Goto A. Gouda H.N. Guerrant R. Gugnani H.C. Gunnell D. Gupta R. Gupta R. Gutierrez R.A. Hafezi-Nejad N. Hagan H. Halasa Y. Hamadeh R.R. Hamavid H. Hammami M. Hankey G.J. Hao Y. Harb H.L. Haro J.M. Havmoeller R. Hay R.J. Hay S. Hedayati M.T. Pi I.B.H. Heydarpour P. Hijar M. Hoek H.W. Hoffman H.J. Hornberger J.C. Hosgood H.D. Hossain M. Hotez P.J. Hoy D.G. Hsairi M. Hu H. Hu G. Huang J.J. Huang C. Huiart L. Husseini A. Iannarone M. Iburg K.M. Innos K. Inoue M. Jacobsen K.H. Jassal S.K. Jeemon P. Jensen P.N. Jha V. Jiang G. Jiang Y. Jonas J.B. Joseph J. Juel K. Kan H. Karch A. Karimkhani C. Karthikeyan G. Katz R. Kaul A. Kawakami N. Kazi D.S. Kemp A.H. Kengne A.P. Khader Y.S. Khalifa S.E.A.H. Khan E.A. Khan G. Khang Y-H. Khonelidze I. Kieling C. Kim D. Kim S. Kimokoti R.W. Kinfu Y. Kinge J.M. Kissela B.M. Kivipelto M. Knibbs L. Knudsen A.K. Kokubo Y. Kosen S. Kramer A. Kravchenko M. Krishnamurthi R.V. Krishnaswami S. Defo B.K. Bicer B.K. Kuipers E.J. Kulkarni V.S. Kumar K. Kumar G.A. Kwan G.F. Lai T. Lalloo R. Lam H. Lan Q. Lansingh V.C. Larson H. Larsson A. Lawrynowicz A.E.B. Leasher J.L. Lee J-T. Leigh J. Leung R. Levi M. Li B. Li Y. Li Y. liang, J.; Lim, S.; Lin, H-H.; Lind, M.; Lindsay, M.P.; Lipshultz, S.E.; Liu, S.; Lloyd, B.K.; Ohno, S.L.; Logroscino, G.; Looker, K.J.; Lopez, A.D.; Lopez-Olmedo, N.; Lortet-Tieulent, J.; Lotufo, P.A.; Low, N.; Lucas, R.M.; Lunevicius, R.; Lyons, R.A.; Ma, J.; Ma, S.; Mackay, M.T.; Majdan, M.; Malekzadeh, R.; Mapoma, C.C.; Marcenes, W.; March, L.M.; Margono, C.; Marks, G.B.; Marzan, M.B.; Masci, J.R.; Mason-Jones, A.J.; Matzopoulos, R.G.; Mayosi, B.M.; Mazorodze, T.T.; McGill, N.W.; McGrath, J.J.; McKee, M.; McLain, A.; McMahon, B.J.; Meaney, P.A.; Mehndiratta, M.M.; Mejia-Rodriguez, F.; Mekonnen, W.; Melaku, Y.A.; Meltzer, M.; Memish, Z.A.; Mensah, G.; Meretoja, A.; Mhimbira, F.A.; Micha, R.; Miller, T.R.; Mills, E.J.; Mitchell, P.B.; Mock, C.N.; Moffitt, T.E.; Ibrahim, N.M.; Mohammad, K.A.; Mokdad, A.H.; Mola, G.L.; Monasta, L.; Montico, M.; Montine, T.J.; Moore, A.R.; Moran, A.E.; Morawska, L.; Mori, R.; Moschandreas, J.; Moturi, W.N.; Moyer, M.; Mozaffarian, D.; Mueller, U.O.; Mukaigawara, M.; Murdoch, M.E.; Murray, J.; Murthy, K.S.; Naghavi, P.; Nahas, Z.; Naheed, A.; Naidoo, K.S.; Naldi, L.; Nand, D.; Nangia, V.; Narayan, K.M.V.; Nash, D.; Nejjari, C.; Neupane, S.P.; Newman, L.M.; Newton, C.R.; Ng, M.; Ngalesoni, F.N.; Nhung, N.T.; Nisar, M.I.; Nolte, S.; Norheim, O.F.; Norman, R.E.; Norrving, B.; Nyakarahuka, L.; Oh, I.H.; Ohkubo, T.; Omer, S.B.; Opio, J.N.; Ortiz, A.; Pandian, J.D.; Panelo, C.I.A.; Papachristou, C.; Park, E-K.; Parry, C.D.; Caicedo, A.J.P.; Patten, S.B.; Paul, V.K.; Pavlin, B.I.; Pearce, N.; Pedraza, L.S.; Pellegrini, C.A.; Pereira, D.M.; Perez-Ruiz, F.P.; Perico, N.; Pervaiz, A.; Pesudovs, K.; Peterson, C.B.; Petzold, M.; Phillips, M.R.; Phillips, D.; Phillips, B.; Piel, F.B.; Plass, D.; Poenaru, D.; Polanczyk, G.V.; Polinder, S.; Pope, C.A.; Popova, S.; Poulton, R.G.; Pourmalek, F.; Prabhakaran, D.; Prasad, N.M.; Qato, D.; Quistberg, D.A.; Rafay, A.; Rahimi, K.; Rahimi-Movaghar, V.; Rahman, S.; Raju, M.; Rakovac, I.; Rana, S.M.; Razavi, H.; Refaat, A.; Rehm, J.; Remuzzi, G.; Resnikoff, S.; Ribeiro, A.L.; Riccio, P.M.; Richardson, L.; Richardus, J.H.; Riederer, A.M.; Robinson, M.; Roca, A.; Rodriguez, A.; Rojas-Rueda, D.; Ronfani, L.; Rothenbacher, D.; Roy, N.; Ruhago, G.M.; Sabin, N.; Sacco, R.L.; Ksoreide, K.; Saha, S.; Sahathevan, R.; Sahraian, M.A.; Sampson, U.; Sanabria, J.R.; Sanchez-Riera, L.; Santos, I.S.; Satpathy, M.; Saunders, J.E.; Sawhney, M.; Saylan, M.I.; Scarborough, P.; Schoettker, B.; Schneider, I.J.C.; Schwebel, D.C.; Scott, J.G.; Seedat, S.; Sepanlou, S.G.; Serdar, B.; Servan-Mori, E.E.; Shackelford, K.; Shaheen, A.; Shahraz, S.; Levy, T.S.; Shangguan, S.; She, J.; Sheikhbahaei, S.; Shepard, D.S.; Shi, P.; Shibuya, K.; Shinohara, Y.; Shiri, R.; Shishani, K.; Shiue, I.; Shrime, M.G.; Sigfusdottir, I.D.; Silberberg, D.H.; Simard, E.P.; Sindi, S.; Singh, J.A.; Singh, L.; Skirbekk, V.; Sliwa, K.; Soljak, M.; Soneji, S.; Soshnikov, S.S.; Speyer, P.; Sposato, L.A.; Sreeramareddy, C.T.; Stoeckl, H.; Stathopoulou, V.K.; Steckling, N.; Stein, M.B.; Stein, D.J.; Steiner, T.J.; Stewart, A.; Stork, E.; Stovner, L.J.; Stroumpoulis, K.; Sturua, L.; Sunguya, B.F.; Swaroop, M.; Sykes, B.L.; Tabb, K.M.; Takahashi, K.; Tan, F.; Tandon, N.; Tanne, D.; Tanner, M.; Tavakkoli, M.; Taylor, H.R.; Te Ao, B.J.; Temesgen, A.M.; Have, M.T.; Tenkorang, E.Y.; Terkawi, A.S.; Theadom, A.M.; Thomas, E.; Thorne-Lyman, A.L.; Thrift, A.G.; Tleyjeh, I.M.; Tonelli, M.; Topouzis, F.; Towbin, J.A.; Toyoshima, H.; Traebert, J.; Tran, B.X.; Trasande, L.; Trillini, M.; Truelsen, T.; Trujillo, U.; Tsilimbaris, M.; Tuzcu, E.M.; Ukwaja, K.N.; Undurraga, E.A.; Uzun, S.B.; van Brakel, W.H.; van de Vijver, S.; Dingenen, R.V.; van Gool, C.H.; Varakin, Y.Y.; Vasankari, T.J.; Vavilala, M.S.; Veerman, L.J.; Velasquez-Melendez, G.; Venketasubramanian, N.; Vijayakumar, L.; Villalpando, S.; Violante, F.S.; Vlassov, V.V.; Waller, S.; Wallin, M.T.; Wan, X.; Wang, L.; Wang, J.L.; Wang, Y.; Warouw, T.S.; Weichenthal, S.; Weiderpass, E.; Weintraub, R.G.; Werdecker, A.; Wessells, K.R.R.; Westerman, R.; Wilkinson, J.D.; Williams, H.C.; Williams, T.N.; Woldeyohannes, S.M.; Wolfe, C.D.A.; Wong, J.Q.; Wong, H.; Woolf, A.D.; Wright, J.L.; Wurtz, B.; Xu, G.; Yang, G.; Yano, Y.; Yenesew, M.A.; Yentur, G.K.; Yip, P.; Yonemoto, N.; Yoon, S-J.; Younis, M.; Yu, C.; Kim, K.Y.; Zaki, M.E.S.; Zhang, Y.; Zhao, Z.; Zhao, Y.; Zhu, J.; Zonies, D.; Zunt, J.R.; Salomon, J.A.; Murray, C.J.L. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015 386 9995 743 800 10.1016/S0140-6736(15)60692-4 26063472
3 Monroe S.M. Harkness K.L. Major depression and its recurrences: Life course matters. Annu. Rev. Clin. Psychol. 2022 18 1 329 357 10.1146/annurev-clinpsy-072220-021440 35216520
4 Lépine J.P. Briley M. The increasing burden of depression. Neuropsychiatr. Dis. Treat. 2011 7 Suppl. 1 3 7 21750622
5 Laursen T.M. Musliner K.L. Benros M.E. Vestergaard M. Munk-Olsen T. Mortality and life expectancy in persons with severe unipolar depression. J. Affect. Disord. 2016 193 203 207 10.1016/j.jad.2015.12.067 26773921
6 Chesney E. Goodwin G.M. Fazel S. Risks of all-cause and suicide mortality in mental disorders: A meta-review. World Psychiatry 2014 13 2 153 160 10.1002/wps.20128 24890068
7 Penninx B.W.J.H. Milaneschi Y. Lamers F. Vogelzangs N. Understanding the somatic consequences of depression: Biological mechanisms and the role of depression symptom profile. BMC Med. 2013 11 1 129 10.1186/1741-7015-11-129 23672628
8 Ruhé H.G. Huyser J. Swinkels J.A. Schene A.H. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: A systematic review. J. Clin. Psychiatry 2006 67 12 1836 1855 10.4088/JCP.v67n1203 17194261
9 Rush A.J. Trivedi M.H. Wisniewski S.R. Stewart J.W. Nierenberg A.A. Thase M.E. Ritz L. Biggs M.M. Warden D. Luther J.F. Shores-Wilson K. Niederehe G. Fava M. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med. 2006 354 12 1231 1242 10.1056/NEJMoa052963 16554525
10 Giakoumatos C.I. Osser D. The psychopharmacology algorithm project at the harvard south shore program: An update on unipolar nonpsychotic depression. Harv. Rev. Psychiatry 2019 27 1 33 52 10.1097/HRP.0000000000000197 30614886
11 Otte C. Gold S.M. Penninx B.W. Pariante C.M. Etkin A. Fava M. Mohr D.C. Schatzberg A.F. Major depressive disorder. Nat. Rev. Dis. Primers 2016 2 1 16065 10.1038/nrdp.2016.65 27629598
12 Ormel J. Oldehinkel A.J. Nolen W.A. Vollebergh W. Psychosocial disability before, during, and after a major depressive episode: A 3-wave population-based study of state, scar, and trait effects. Arch. Gen. Psychiatry 2004 61 4 387 392 10.1001/archpsyc.61.4.387 15066897
13 Wittchen H.U. Jacobi F. Rehm J. Gustavsson A. Svensson M. Jönsson B. Olesen J. Allgulander C. Alonso J. Faravelli C. Fratiglioni L. Jennum P. Lieb R. Maercker A. van Os J. Preisig M. Salvador-Carulla L. Simon R. Steinhausen H.C. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011 21 9 655 679 10.1016/j.euroneuro.2011.07.018 21896369
14 Menke A. Precision pharmacotherapy: Psychiatry’s future direction in preventing, diagnosing, and treating mental disorders. Pharm. Genomics Pers. Med. 2018 11 211 222 10.2147/PGPM.S146110 30510440
15 Menke A. Is the HPA axis as target for depression outdated, or is there a new hope? Front. Psychiatry 2019 10 101 10.3389/fpsyt.2019.00101 30890970
16 Mora C. Zonca V. Riva M.A. Cattaneo A. Blood biomarkers and treatment response in major depression. Expert Rev. Mol. Diagn. 2018 18 6 513 529 10.1080/14737159.2018.1470927 29701114
17 Kadriu B. Greenwald M. Henter I.D. Gilbert J.R. Kraus C. Park L.T. Zarate C.A. Jr Ketamine and serotonergic psychedelics: Common mechanisms underlying the effects of rapid-acting antidepressants. Int. J. Neuropsychopharmacol. 2021 24 1 8 21 10.1093/ijnp/pyaa087 33252694
18 Ionescu D.F. Fu D.J. Qiu X. Lane R. Lim P. Kasper S. Hough D. Drevets W.C. Manji H. Canuso C.M. Esketamine nasal spray for rapid reduction of depressive symptoms in patients with major depressive disorder who have active suicide ideation with intent: Results of a Phase 3, double-blind, randomized study (ASPIRE II). Int. J. Neuropsychopharmacol. 2021 24 1 22 31 10.1093/ijnp/pyaa068 32861217
19 Sullivan P.F. Neale M.C. Kendler K.S. Genetic epidemiology of major depression: Review and meta-analysis. Am. J. Psychiatry 2000 157 10 1552 1562 10.1176/appi.ajp.157.10.1552 11007705
20 Klengel T. Binder E.B. Epigenetics of stress-related psychiatric disorders and gene × environment interactions. Neuron 2015 86 6 1343 1357 10.1016/j.neuron.2015.05.036 26087162
21 Binder EB Dissecting the molecular mechanisms of gene x environment interactions: Implications for diagnosis and treatment of stress-related psychiatric disorders. Eur. J. Psychotraumatol. 2017 8 sup5 1412745 10.1080/20008198.2017.1412745 29372006
22 Menke A. Binder E.B. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin. Neurosci. 2014 16 3 395 404 10.31887/DCNS.2014.16.3/amenke 25364288
23 Heim C. Nemeroff C.B. The role of childhood trauma in the neurobiology of mood and anxiety disorders: Preclinical and clinical studies. Biol. Psychiatry 2001 49 12 1023 1039 10.1016/S0006-3223(01)01157-X 11430844
24 Hu P. Maita I. Phan M.L. Gu E. Kwok C. Dieterich A. Gergues M.M. Yohn C.N. Wang Y. Zhou J.N. Qi X.R. Swaab D.F. Pang Z.P. Lucassen P.J. Roepke T.A. Samuels B.A. Early-life stress alters affective behaviors in adult mice through persistent activation of CRH-BDNF signaling in the oval bed nucleus of the stria terminalis. Transl. Psychiatry 2020 10 1 396 10.1038/s41398-020-01070-3 33177511
25 Zimmermann P. Brückl T. Nocon A. Pfister H. Binder E.B. Uhr M. Lieb R. Moffitt T.E. Caspi A. Holsboer F. Ising M. Interaction of FKBP5 gene variants and adverse life events in predicting depression onset: Results from a 10-year prospective community study. Am. J. Psychiatry 2011 168 10 1107 1116 10.1176/appi.ajp.2011.10111577 21865530
26 Binder E.B. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology 2009 34 Suppl. 1 S186 S195 10.1016/j.psyneuen.2009.05.021 19560279
27 McEwen B.S. Physiology and neurobiology of stress and adaptation: Central role of the brain. Physiol. Rev. 2007 87 3 873 904 10.1152/physrev.00041.2006 17615391
28 Danese A.J. Lewis S. Psychoneuroimmunology of early-life stress: The hidden wounds of childhood trauma? Neuropsychopharmacology 2017 42 1 99 114 10.1038/npp.2016.198 27629365
29 Kuhlman K.R. Chiang J.J. Horn S. Bower J.E. Developmental psychoneuroendocrine and psychoneuroimmune pathways from childhood adversity to disease. Neurosci. Biobehav. Rev. 2017 80 166 184 10.1016/j.neubiorev.2017.05.020 28577879
30 Kessler R.C. The effects of stressful life events on depression. Annu. Rev. Psychol. 1997 48 1 191 214 10.1146/annurev.psych.48.1.191 9046559
31 Menke A. Nitschke F. Hellmuth A. Helmel J. Wurst C. Stonawski S. Blickle M. Weiß C. Weber H. Hommers L. Domschke K. Deckert J. Stress impairs response to antidepressants via HPA axis and immune system activation. Brain Behav. Immun. 2021 93 132 140 10.1016/j.bbi.2020.12.033 33422640
32 Yang J.Z. Kang C.Y. Yuan J. Zhang Y. Wei Y.J. Xu L. Zhou F. Fan X. Effect of adverse childhood experiences on hypothalamic–pituitary–adrenal (HPA) axis function and antidepressant efficacy in untreated first episode patients with major depressive disorder. Psychoneuroendocrinology 2021 134 105432 10.1016/j.psyneuen.2021.105432 34607174
33 Knorr U. Vinberg M. Kessing L.V. Wetterslev J. Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. Psychoneuroendocrinology 2010 35 9 1275 1286 10.1016/j.psyneuen.2010.04.001 20447770
34 Stetler C. Miller G.E. Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. Psychosom. Med. 2011 73 2 114 126 10.1097/PSY.0b013e31820ad12b 21257974
35 Holsboer F. Stress, hypercortisolism and corticosteroid receptors in depression: Implicatons for therapy. J. Affect. Disord. 2001 62 1-2 77 91 10.1016/S0165-0327(00)00352-9 11172875
36 Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000 23 5 477 501 10.1016/S0893-133X(00)00159-7 11027914
37 Vale W. Spiess J. Rivier C. Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981 213 4514 1394 1397 10.1126/science.6267699 6267699
38 Schatzberg A.F. Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamic–pituitary–adrenal (HPA) axis in the pathogenesis of psychotic major depression. World J. Biol. Psychiatry 2015 16 1 2 11 10.3109/15622975.2014.916414 24933348
39 Qi X.R. Kamphuis W. Wang S. Wang Q. Lucassen P.J. Zhou J.N. Swaab D.F. Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients. Psychoneuroendocrinology 2013 38 6 863 870 10.1016/j.psyneuen.2012.09.014 23137715
40 Qi C.C. Zhang Z. Fang H. Liu J. Zhou N. Ge J.F. Chen F.H. Xiang C.B. Zhou J.N. Antidepressant effects of abscisic acid mediated by the downregulation of corticotrophin-releasing hormone gene expression in rats. Int. J. Neuropsychopharmacol. 2014 18 4 pyu006 25552429
41 Hu P. van Dam A.M. Wang Y. Lucassen P.J. Zhou J.N. Retinoic acid and depressive disorders: Evidence and possible neurobiological mechanisms. Neurosci. Biobehav. Rev. 2020 112 376 391 10.1016/j.neubiorev.2020.02.013 32070693
42 Rotondo F. Butz H. Syro L.V. Yousef G.M. Di Ieva A. Restrepo L.M. Quintanar-Stephano A. Berczi I. Kovacs K. Arginine vasopressin (AVP): A review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. Pituitary 2016 19 4 345 355 10.1007/s11102-015-0703-0 26762848
43 Pariante C.M. Miller A.H. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol. Psychiatry 2001 49 5 391 404 10.1016/S0006-3223(00)01088-X 11274650
44 Pariante C.M. Glucocorticoid receptor function in vitro in patients with major depression. Stress 2004 7 4 209 219 10.1080/10253890500069650 16019586
45 Young E.A. Lopez J.F. Murphy-Weinberg V. Watson S.J. Akil H. Mineralocorticoid receptor function in major depression. Arch. Gen. Psychiatry 2003 60 1 24 28 10.1001/archpsyc.60.1.24 12511169
46 McEwen B.S. Protective and damaging effects of stress mediators. N. Engl. J. Med. 1998 338 3 171 179 10.1056/NEJM199801153380307 9428819
47 Leistner C. Menke A. How to measure glucocorticoid receptor’s sensitivity in patients with stress-related psychiatric disorders. Psychoneuroendocrinology 2018 91 235 260 10.1016/j.psyneuen.2018.01.023 29449045
48 Carroll B.J. Martin F.I.R. Davies B. Resistance to suppression by dexamethasone of plasma 11-O.H.C.S. levels in severe depressive illness. BMJ 1968 3 5613 285 287 10.1136/bmj.3.5613.285 4385601
49 Carroll B.J. Feinberg M. Greden J.F. Tarika J. Albala A.A. Haskett R.F. James N.M. Kronfol Z. Lohr N. Steiner M. de Vigne J.P. Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 1981 38 1 15 22 10.1001/archpsyc.1981.01780260017001 7458567
50 Nelson J.C. Davis J.M. DST studies in psychotic depression: A meta-analysis. Am. J. Psychiatry 1997 154 11 1497 1503 10.1176/ajp.154.11.1497 9356556
51 Nierenberg A.A. Feinstein A.R. How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test. JAMA 1988 259 11 1699 1702 10.1001/jama.1988.03720110061036 3278149
52 Gervasoni N. Bertschy G. Osiek C. Perret G. Denis R. Golaz J. Rossier M.F. Bondolfi G. Aubry J.M. Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode. J. Psychiatr. Res. 2004 38 6 553 557 10.1016/j.jpsychires.2004.04.008 15458850
53 Carpenter L.L. Ross N.S. Tyrka A.R. Anderson G.M. Kelly M. Price L.H. Dex/CRH test cortisol response in outpatients with major depression and matched healthy controls. Psychoneuroendocrinology 2009 34 8 1208 1213 10.1016/j.psyneuen.2009.03.009 19375869
54 Holsboer F. Bender W. Benkert O. Klein H.E. Schmauss M. Diagnostic value of dexamethasone suppression test in depression. Lancet 1980 316 8196 706 10.1016/S0140-6736(80)92755-5 6106823
55 Arana G.W. Baldessarini R.J. Ornsteen M. The dexamethasone suppression test for diagnosis and prognosis in psychiatry. Commentary and review. Arch. Gen. Psychiatry 1985 42 12 1193 1204 10.1001/archpsyc.1985.01790350067012 3000317
56 Bardeleben U. Holsboer F. Cortisol response to a combined dexamethasone-human corticotrophin-releasing hormone challenge in patients with depression. J. Neuroendocrinol. 1989 1 6 485 488 10.1111/j.1365-2826.1989.tb00150.x 19210420
57 Heuser I. Yassouridis A. Holsboer F. The combined dexamethasone/CRH test: A refined laboratory test for psychiatric disorders. J. Psychiatr. Res. 1994 28 4 341 356 10.1016/0022-3956(94)90017-5 7877114
58 Modell S. Yassouridis A. Huber J. Holsboer F. Corticosteroid receptor function is decreased in depressed patients. Neuroendocrinology 1997 65 3 216 222 10.1159/000127275 9088003
59 Kunugi H. Ida I. Owashi T. Kimura M. Inoue Y. Nakagawa S. Yabana T. Urushibara T. Kanai R. Aihara M. Yuuki N. Otsubo T. Oshima A. Kudo K. Inoue T. Kitaichi Y. Shirakawa O. Isogawa K. Nagayama H. Kamijima K. Nanko S. Kanba S. Higuchi T. Mikuni M. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: A multicenter study. Neuropsychopharmacology 2006 31 1 212 220 10.1038/sj.npp.1300868 16123748
60 Ising M. Horstmann S. Kloiber S. Lucae S. Binder E.B. Kern N. Künzel H.E. Pfennig A. Uhr M. Holsboer F. Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression - a potential biomarker? Biol. Psychiatry 2007 62 1 47 54 10.1016/j.biopsych.2006.07.039 17123470
61 Zobel A.W. Nickel T. Sonntag A. Uhr M. Holsboer F. Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. J. Psychiatr. Res. 2001 35 2 83 94 10.1016/S0022-3956(01)00013-9 11377437
62 Appelhof B.C. Huyser J. Verweij M. Brouwer J.P. van Dyck R. Fliers E. Hoogendijk W.J.G. Tijssen J.G.P. Wiersinga W.M. Schene A.H. Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biol. Psychiatry 2006 59 8 696 701 10.1016/j.biopsych.2005.09.008 16368077
63 Coryell W. Schlesser M. The dexamethasone suppression test and suicide prediction. Am. J. Psychiatry 2001 158 5 748 753 10.1176/appi.ajp.158.5.748 11329397
64 Hennings J.M. Ising M. Uhr M. Holsboer F. Lucae S. Recurrent suicide attempts affect normalization of HPA axis dysregulation after recovery from major depression. Front. Psychiatry 2022 13 937582 10.3389/fpsyt.2022.937582 36032226
65 Menke A. Arloth J. Best J. Namendorf C. Gerlach T. Czamara D. Lucae S. Dunlop B.W. Crowe T.M. Garlow S.J. Nemeroff C.B. Ritchie J.C. Craighead W.E. Mayberg H.S. Rex-Haffner M. Binder E.B. Uhr M. Time-dependent effects of dexamethasone plasma concentrations on glucocorticoid receptor challenge tests. Psychoneuroendocrinology 2016 69 161 171 10.1016/j.psyneuen.2016.04.003 27107207
66 Leistner C. Menke A. Hypothalamic–pituitary–adrenal axis and stress. Handb. Clin. Neurol. 2020 175 55 64 10.1016/B978-0-444-64123-6.00004-7 33008543
67 Menke A. Arloth J. Pütz B. Weber P. Klengel T. Mehta D. Gonik M. Rex-Haffner M. Rubel J. Uhr M. Lucae S. Deussing J.M. Müller-Myhsok B. Holsboer F. Binder E.B. Dexamethasone stimulated gene expression in peripheral blood is a sensitive marker for glucocorticoid receptor resistance in depressed patients. Neuropsychopharmacology 2012 37 6 1455 1464 10.1038/npp.2011.331 22237309
68 Menke A. Rex-Haffner M. Klengel T. Binder E.B. Mehta D. Peripheral blood gene expression: It all boils down to the RNA collection tubes. BMC Res. Notes 2012 5 1 1 10.1186/1756-0500-5-1 22214347
69 Menke A. Arloth J. Gerber M. Rex-Haffner M. Uhr M. Holsboer F. Binder E.B. Holsboer-Trachsler E. Beck J. Dexamethasone stimulated gene expression in peripheral blood indicates glucocorticoid-receptor hypersensitivity in job-related exhaustion. Psychoneuroendocrinology 2014 44 35 46 10.1016/j.psyneuen.2014.02.013 24767618
70 Menke A. Lehrieder D. Fietz J. Leistner C. Wurst C. Stonawski S. Reitz J. Lechner K. Busch Y. Weber H. Deckert J. Domschke K. Childhood trauma dependent anxious depression sensitizes HPA axis function. Psychoneuroendocrinology 2018 98 22 29 10.1016/j.psyneuen.2018.07.025 30086534
71 Rampp C. Eichelkraut A. Best J. Czamara D. Rex-Haffner M. Uhr M. Binder E.B. Menke A. Sex-related differential response to dexamethasone in endocrine and immune measures in depressed in-patients and healthy controls. J. Psychiatr. Res. 2018 98 107 115 10.1016/j.jpsychires.2017.12.020 29331929
72 Arloth J. Bogdan R. Weber P. Frishman G. Menke A. Wagner K.V. Balsevich G. Schmidt M.V. Karbalai N. Czamara D. Altmann A. Trümbach D. Wurst W. Mehta D. Uhr M. Klengel T. Erhardt A. Carey C.E. Conley E.D. Ruepp A. Müller-Myhsok B. Hariri A.R. Binder E.B. Ripke S. Wray N.R. Lewis C.M. Hamilton S.P. Weissman M.M. Breen G. Byrne E.M. Blackwood D.H.R. Boomsma D.I. Cichon S. Heath A.C. Holsboer F. Lucae S. Madden P.A.F. Martin N.G. McGuffin P. Muglia P. Noethen M.M. Penninx B.P. Pergadia M.L. Potash J.B. Rietschel M. Lin D. Müller-Myhsok B. Shi J. Steinberg S. Grabe H.J. Lichtenstein P. Magnusson P. Perlis R.H. Preisig M. Smoller J.W. Stefansson K. Uher R. Kutalik Z. Tansey K.E. Teumer A. Viktorin A. Barnes M.R. Bettecken T. Binder E.B. Breuer R. Castro V.M. Churchill S.E. Coryell W.H. Craddock N. Craig I.W. Czamara D. De Geus E.J. Degenhardt F. Farmer A.E. Fava M. Frank J. Gainer V.S. Gallagher P.J. Gordon S.D. Goryachev S. Gross M. Guipponi M. Henders A.K. Herms S. Hickie I.B. Hoefels S. Hoogendijk W. Hottenga J.J. Iosifescu D.V. Ising M. Jones I. Jones L. Jung-Ying T. Knowles J.A. Kohane I.S. Kohli M.A. Korszun A. Landen M. Lawson W.B. Lewis G. MacIntyre D. Maier W. Mattheisen M. McGrath P.J. McIntosh A. McLean A. Middeldorp C.M. Middleton L. Montgomery G.M. Murphy S.N. Nauck M. Nolen W.A. Nyholt D.R. O’Donovan M. Oskarsson H. Pedersen N. Scheftner W.A. Schulz A. Schulze T.G. Shyn S.I. Sigurdsson E. Slager S.L. Smit J.H. Stefansson H. Steffens M. Thorgeirsson T. Tozzi F. Treutlein J. Uhr M. van den Oord E.J.C.G. Van Grootheest G. Völzke H. Weilburg J.B. Willemsen G. Zitman F.G. Neale B. Daly M. Levinson D.F. Sullivan P.F. Genetic differences in the immediate transcriptome response to stress predict risk-related brain function and psychiatric disorders. Neuron 2015 86 5 1189 1202 10.1016/j.neuron.2015.05.034 26050039
73 Wiechmann T. Röh S. Sauer S. Czamara D. Arloth J. Ködel M. Beintner M. Knop L. Menke A. Binder E.B. Provençal N. Identification of dynamic glucocorticoid-induced methylation changes at the FKBP5 locus. Clin. Epigenetics 2019 11 1 83 10.1186/s13148-019-0682-5 31122292
74 Smith S.M. Vale W.W. The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin. Neurosci. 2006 8 4 383 395 10.31887/DCNS.2006.8.4/ssmith 17290797
75 de Kloet E.R. Joëls M. Holsboer F. Stress and the brain: From adaptation to disease. Nat. Rev. Neurosci. 2005 6 6 463 475 10.1038/nrn1683 15891777
76 Schatzberg A.F. Keller J. Tennakoon L. Lembke A. Williams G. Kraemer F.B. Sarginson J.E. Lazzeroni L.C. Murphy G.M. HPA axis genetic variation, cortisol and psychosis in major depression. Mol. Psychiatry 2014 19 2 220 227 10.1038/mp.2013.129 24166410
77 Keller J. Flores B. Gomez R.G. Solvason H.B. Kenna H. Williams G.H. Schatzberg A.F. Cortisol circadian rhythm alterations in psychotic major depression. Biol. Psychiatry 2006 60 3 275 281 10.1016/j.biopsych.2005.10.014 16458262
78 Dwyer J.B. Aftab A. Radhakrishnan R. Widge A. Rodriguez C.I. Carpenter L.L. Nemeroff C.B. McDonald W.M. Kalin N.H. Hormonal treatments for major depressive disorder: State of the art. Am. J. Psychiatry 2020 177 8 686 705 10.1176/appi.ajp.2020.19080848 32456504
79 Ding Y. Wei Z. Yan H. Guo W. Efficacy of treatments targeting hypothalamic-pituitary-adrenal systems for major depressive disorder: A meta-analysis. Front. Pharmacol. 2021 12 732157 10.3389/fphar.2021.732157 34566653
80 Aguilera G. Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic–pituitary–adrenal axis: Implications for stress adaptation. Regul. Pept. 2000 96 1-2 23 29 10.1016/S0167-0115(00)00196-8 11102648
81 Peter J. Burbach H. Adan R.A.H. Lolait S.J. van Leeuwen F.W. Mezey E. Palkovits M. Barberis C. Molecular neurobiology and pharmacology of the Vasopressin/Oxytocin receptor family. Cell. Mol. Neurobiol. 1995 15 5 573 595 10.1007/BF02071318 8719042
82 Rabadan-Diehl C. Lolait S.J. Aguilera G. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat. J. Neuroendocrinol. 1995 7 12 903 910 10.1111/j.1365-2826.1995.tb00734.x 8745267
83 Meynen G. Unmehopa U.A. van Heerikhuize J.J. Hofman M.A. Swaab D.F. Hoogendijk W.J.G. Increased arginine vasopressin mRNA expression in the human hypothalamus in depression: A preliminary report. Biol. Psychiatry 2006 60 8 892 895 10.1016/j.biopsych.2005.12.010 16499879
84 Holsboer F. Ising M. Hypothalamic stress systems in mood disorders. Handb. Clin. Neurol. 2021 182 33 48 10.1016/B978-0-12-819973-2.00003-4 34266603
85 Chaki S. Vasopressin V1B receptor antagonists as potential antidepressants. Int. J. Neuropsychopharmacol. 2021 24 6 450 463 10.1093/ijnp/pyab013 33733667
86 Griebel G. Beeské S. Stahl S.M. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: Results from 4 randomized, double-blind, placebo-controlled studies. J. Clin. Psychiatry 2012 73 11 1403 1411 10.4088/JCP.12m07804 23146246
87 Katz D.A. Locke C. Greco N. Liu W. Tracy K.A. Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial. Brain Behav. 2017 7 3 e00628 10.1002/brb3.628 28293470
88 Kamiya M. Sabia H.D. Marella J. Fava M. Nemeroff C.B. Umeuchi H. Iijima M. Chaki S. Nishino I. Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: A randomized, double-blind, placebo-controlled study. J. Psychiatr. Res. 2020 128 43 51 10.1016/j.jpsychires.2020.05.017 32521250
89 Watson S. Gallagher P. Porter R.J. Smith M.S. Herron L.J. Bulmer S. Young A.H. Ferrier I.N. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol. Psychiatry 2012 72 11 943 949 10.1016/j.biopsych.2012.05.029 22770649
90 Belanoff J.K. Flores B.H. Kalezhan M. Sund B. Schatzberg A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 2001 21 5 516 521 10.1097/00004714-200110000-00009 11593077
91 Flores B.H. Kenna H. Keller J. Solvason H.B. Schatzberg A.F. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 2006 31 3 628 636 10.1038/sj.npp.1300884 16160710
92 DeBattista C. Belanoff J. Glass S. Khan A. Horne R.L. Blasey C. Carpenter L.L. Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol. Psychiatry 2006 60 12 1343 1349 10.1016/j.biopsych.2006.05.034 16889757
93 Belanoff J.K. Rothschild A.J. Cassidy F. DeBattista C. Baulieu E.E. Schold C. Schatzberg A.F. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatry 2002 52 5 386 392 10.1016/S0006-3223(02)01432-4 12242054
94 Simpson G.M. Sheshai A.E. Loza N. Kingsbury S.J. Fayek M. Rady A. Fawzy W. An 8-week open-label trial of a 6-day course of mifepristone for the treatment of psychotic depression. J. Clin. Psychiatry 2005 66 5 598 602 10.4088/JCP.v66n0509 15889946
95 Blasey C.M. DeBattista C. Roe R. Block T. Belanoff J.K. A multisite trial of mifepristone for the treatment of psychotic depression: A site-by-treatment interaction. Contemp. Clin. Trials 2009 30 4 284 288 10.1016/j.cct.2009.03.001 19318138
96 Block T.S. Kushner H. Kalin N. Nelson C. Belanoff J. Schatzberg A. Combined analysis of mifepristone for psychotic depression: Plasma levels associated with clinical response. Biol. Psychiatry 2018 84 1 46 54 10.1016/j.biopsych.2018.01.008 29523415
97 Holsboer F. CRHR1 antagonists as novel treatment strategies. CNS Spectr. 2001 6 7 590 594 10.1017/S1092852900002133 15573022
98 Zhou J.N. Fang H. Transcriptional regulation of corticotropin-releasing hormone gene in stress response. IBRO Rep. 2018 5 137 146 10.1016/j.ibror.2018.08.003 30591954
99 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 1999 33 3 181 214 10.1016/S0022-3956(98)90056-5 10367986
100 Owens M.J. Nemeroff C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 1991 43 4 425 473 1775506
101 Zobel A.W. Nickel T. Künzel H.E. Ackl N. Sonntag A. Ising M. Holsboer F. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 2000 34 3 171 181 10.1016/S0022-3956(00)00016-9 10867111
102 Binneman B. Feltner D. Kolluri S. Shi Y. Qiu R. Stiger T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry 2008 165 5 617 620 10.1176/appi.ajp.2008.07071199 18413705
103 Spierling S.R. Zorrilla E.P. Don’t stress about CRF: Assessing the translational failures of CRF1antagonists. Psychopharmacology 2017 234 9-10 1467 1481 10.1007/s00213-017-4556-2 28265716
104 Schwandt M.L. Cortes C.R. Kwako L.E. George D.T. Momenan R. Sinha R. Grigoriadis D.E. Pich E.M. Leggio L. Heilig M. The CRF1 antagonist verucerfont in anxious alcohol-dependent women: Translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology 2016 41 12 2818 2829 10.1038/npp.2016.61 27109623
105 Dunlop B.W. Rothbaum B.O. Binder E.B. Duncan E. Harvey P.D. Jovanovic T. Kelley M.E. Kinkead B. Kutner M. Iosifescu D.V. Mathew S.J. Neylan T.C. Kilts C.D. Nemeroff C.B. Mayberg H.S. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials 2014 15 1 240 10.1186/1745-6215-15-240 24950747
106 Dunlop B.W. Binder E.B. Iosifescu D. Mathew S.J. Neylan T.C. Pape J.C. Carrillo-Roa T. Green C. Kinkead B. Grigoriadis D. Rothbaum B.O. Nemeroff C.B. Mayberg H.S. Corticotropin-releasing factor receptor 1 antagonism is ineffective for women with posttraumatic stress disorder. Biol. Psychiatry 2017 82 12 866 874 10.1016/j.biopsych.2017.06.024 28793974
107 Binder E.B. Salyakina D. Lichtner P. Wochnik G.M. Ising M. Pütz B. Papiol S. Seaman S. Lucae S. Kohli M.A. Nickel T. Künzel H.E. Fuchs B. Majer M. Pfennig A. Kern N. Brunner J. Modell S. Baghai T. Deiml T. Zill P. Bondy B. Rupprecht R. Messer T. Köhnlein O. Dabitz H. Brückl T. Müller N. Pfister H. Lieb R. Mueller J.C. Lõhmussaar E. Strom T.M. Bettecken T. Meitinger T. Uhr M. Rein T. Holsboer F. Muller-Myhsok B. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat. Genet. 2004 36 12 1319 1325 10.1038/ng1479 15565110
108 Matosin N. Halldorsdottir T. Binder E.B. Understanding the molecular mechanisms underpinning gene by environment interactions in psychiatric disorders: The FKBP5 Model. Biol. Psychiatry 2018 83 10 821 830 10.1016/j.biopsych.2018.01.021 29573791
109 Martins J. Yusupov N. Binder E.B. Brückl T.M. Czamara D. Early adversity as the prototype gene × environment interaction in mental disorders? Pharmacol. Biochem. Behav. 2022 215 173371 10.1016/j.pbb.2022.173371 35271857
110 Klengel T. Mehta D. Anacker C. Rex-Haffner M. Pruessner J.C. Pariante C.M. Pace T.W.W. Mercer K.B. Mayberg H.S. Bradley B. Nemeroff C.B. Holsboer F. Heim C.M. Ressler K.J. Rein T. Binder E.B. Allele-specific FKBP5 DNA demethylation mediates gene–childhood trauma interactions. Nat. Neurosci. 2013 16 1 33 41 10.1038/nn.3275 23201972
111 Tatro E.T. Everall I.P. Masliah E. Hult B.J. Lucero G. Chana G. Soontornniyomkij V. Achim C.L. Differential expression of immunophilins FKBP51 and FKBP52 in the frontal cortex of HIV-infected patients with major depressive disorder. J. Neuroimmune Pharmacol. 2009 4 2 218 226 10.1007/s11481-009-9146-6 19199039
112 Chen H. Wang N. Zhao X. Ross C.A. O’Shea K.S. McInnis M.G. Gene expression alterations in bipolar disorder postmortem brains. Bipolar Disord. 2013 15 2 177 187 10.1111/bdi.12039 23360497
113 Sinclair D. Fillman S.G. Webster M.J. Weickert C.S. Dysregulation of glucocorticoid receptor co-factors FKBP5, BAG1 and PTGES3 in prefrontal cortex in psychotic illness. Sci. Rep. 2013 3 1 3539 10.1038/srep03539 24345775
114 Young K.A. Thompson P.M. Cruz D.A. Williamson D.E. Selemon L.D. BA11 FKBP5 expression levels correlate with dendritic spine density in postmortem PTSD and controls. Neurobiol. Stress 2015 2 67 72 10.1016/j.ynstr.2015.07.002 26844242
115 Hawn S.E. Sheerin C.M. Lind M.J. Hicks T.A. Marraccini M.E. Bountress K. Bacanu S.A. Nugent N.R. Amstadter A.B. GxE effects of FKBP5 and traumatic life events on PTSD: A meta-analysis. J. Affect. Disord. 2019 243 455 462 10.1016/j.jad.2018.09.058 30273884
116 Kim H.J. Jin H.J. Polymorphisms in the FKBP5 gene are associated with attention deficit and hyperactivity disorder in Korean children. Behav. Brain Res. 2021 414 113508 10.1016/j.bbr.2021.113508 34352291
117 Lobo J.J. Ayoub L.J. Moayedi M. Linnstaedt S.D. Hippocampal volume, FKBP5 genetic risk alleles, and childhood trauma interact to increase vulnerability to chronic multisite musculoskeletal pain. Sci. Rep. 2022 12 1 6511 10.1038/s41598-022-10411-9 35444168
118 Bortsov A.V. Smith J.E. Diatchenko L. Soward A.C. Ulirsch J.C. Rossi C. Swor R.A. Hauda W.E. Peak D.A. Jones J.S. Holbrook D. Rathlev N.K. Foley K.A. Lee D.C. Collette R. Domeier R.M. Hendry P.L. McLean S.A. Polymorphisms in the glucocorticoid receptor co-chaperone FKBP5 predict persistent musculoskeletal pain after traumatic stress exposure. Pain 2013 154 8 1419 1426 10.1016/j.pain.2013.04.037 23707272
119 Strączkowski, M.; Stefanowicz, M.; Matulewicz, N.; Nikołajuk, A.; Karczewska-Kupczewska, M. Relation of adipose tissue and skeletal muscle FKBP5 expression with insulin sensitivity and the regulation of FKBP5 by insulin and free fatty acids. Endocrine 2022 76 3 536 542 10.1007/s12020-022-03018-7 35212883
120 Smedlund K.B. Sanchez E.R. Hinds T.D. Jr FKBP51 and the molecular chaperoning of metabolism. Trends Endocrinol. Metab. 2021 32 11 862 874 10.1016/j.tem.2021.08.003 34481731
121 Ising M. Maccarrone G. Brückl T. Scheuer S. Hennings J. Holsboer F. Turck C. Uhr M. Lucae S. FKBP5 gene expression predicts antidepressant treatment outcome in depression. Int. J. Mol. Sci. 2019 20 3 485 10.3390/ijms20030485 30678080
122 Schmidt M.V. Paez-Pereda M. Holsboer F. Hausch F. The prospect of FKBP51 as a drug target. ChemMedChem 2012 7 8 1351 1359 10.1002/cmdc.201200137 22581765
123 Gaali S. Gopalakrishnan R. Wang Y. Kozany C. Hausch F. The chemical biology of immunophilin ligands. Curr. Med. Chem. 2011 18 35 5355 5379 10.2174/092986711798194342 22087830
124 Blackburn E.A. Walkinshaw M.D. Targeting FKBP isoforms with small-molecule ligands. Curr. Opin. Pharmacol. 2011 11 4 365 371 10.1016/j.coph.2011.04.007 21803654
125 Kolos J.M. Voll A.M. Bauder M. Hausch F. FKBP Ligands—Where We Are and Where to Go? Front. Pharmacol. 2018 9 1425 10.3389/fphar.2018.01425 30568592
126 Gaali S. Kirschner A. Cuboni S. Hartmann J. Kozany C. Balsevich G. Namendorf C. Fernandez-Vizarra P. Sippel C. Zannas A.S. Draenert R. Binder E.B. Almeida O.F.X. Rühter G. Uhr M. Schmidt M.V. Touma C. Bracher A. Hausch F. Selective inhibitors of the FK506-binding protein 51 by induced fit. Nat. Chem. Biol. 2015 11 1 33 37 10.1038/nchembio.1699 25436518
127 Balsevich G. Häusl A.S. Meyer C.W. Karamihalev S. Feng X. Pöhlmann M.L. Dournes C. Uribe-Marino A. Santarelli S. Labermaier C. Hafner K. Mao T. Breitsamer M. Theodoropoulou M. Namendorf C. Uhr M. Paez-Pereda M. Winter G. Hausch F. Chen A. Tschöp M.H. Rein T. Gassen N.C. Schmidt M.V. Stress-responsive FKBP51 regulates AKT2-AS160 signaling and metabolic function. Nat. Commun. 2017 8 1 1725 10.1038/s41467-017-01783-y 29170369
128 Bauder M. Meyners C. Purder P.L. Merz S. Sugiarto W.O. Voll A.M. Heymann T. Hausch F. Structure-based design of high-affinity macrocyclic FKBP51 inhibitors. J. Med. Chem. 2021 64 6 3320 3349 10.1021/acs.jmedchem.0c02195 33666419
129 Hartmann J. Bajaj T. Klengel C. Chatzinakos C. Ebert T. Dedic N. McCullough K.M. Lardenoije R. Joëls M. Meijer O.C. McCann K.E. Dudek S.M. Sarabdjitsingh R.A. Daskalakis N.P. Klengel T. Gassen N.C. Schmidt M.V. Ressler K.J. Mineralocorticoid receptors dampen glucocorticoid receptor sensitivity to stress via regulation of FKBP5. Cell Rep. 2021 35 9 109185 10.1016/j.celrep.2021.109185 34077736
130 Zhao J. Verwer R.W.H. Gao S.F. Qi X.R. Lucassen P.J. Kessels H.W. Swaab D.F. Prefrontal alterations in GABAergic and glutamatergic gene expression in relation to depression and suicide. J. Psychiatr. Res. 2018 102 261 274 10.1016/j.jpsychires.2018.04.020 29753198
131 Wu X. Balesar R. Lu J. Farajnia S. Zhu Q. Huang M. Bao A.M. Swaab D.F. Increased glutamic acid decarboxylase expression in the hypothalamic suprachiasmatic nucleus in depression. Brain Struct. Funct. 2017 222 9 4079 4088 10.1007/s00429-017-1442-y 28608287
132 Hashimoto K. Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin. Neurosci. 2019 73 10 613 627 10.1111/pcn.12902 31215725
133 Fukumoto K. Toki H. Iijima M. Hashihayata T. Yamaguchi J. Hashimoto K. Chaki S. Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-. Ketamine. J. Pharmacol. Exp. Ther. 2017 361 1 9 16 10.1124/jpet.116.239228 28115553
134 Zanos P. Moaddel R. Morris P.J. Georgiou P. Fischell J. Elmer G.I. Alkondon M. Yuan P. Pribut H.J. Singh N.S. Dossou K.S.S. Fang Y. Huang X.P. Mayo C.L. Wainer I.W. Albuquerque E.X. Thompson S.M. Thomas C.J. Zarate C.A. Jr Gould T.D. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016 533 7604 481 486 10.1038/nature17998 27144355
135 Anderzhanova E. Hafner K. Genewsky A.J. Soliman A. Pöhlmann M.L. Schmidt M.V. Blum R. Wotjak C.T. Gassen N.C. The stress susceptibility factor FKBP51 controls S-ketamine-evoked release of mBDNF in the prefrontal cortex of mice. Neurobiol. Stress 2020 13 100239 10.1016/j.ynstr.2020.100239 33344695
136 Gassen N.C. Hartmann J. Zannas A.S. Kretzschmar A. Zschocke J. Maccarrone G. Hafner K. Zellner A. Kollmannsberger L.K. Wagner K.V. Mehta D. Kloiber S. Turck C.W. Lucae S. Chrousos G.P. Holsboer F. Binder E.B. Ising M. Schmidt M.V. Rein T. FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications. Mol. Psychiatry 2016 21 2 277 289 10.1038/mp.2015.38 25849320
137 Cattaneo A. Riva M.A. STRESS-induced mechanisms in mental illness: A role for glucocorticoid signalling. J. Steroid Biochem. Mol. Biol. 2016 160 169 174 26241031
138 Cattaneo A. Macchi F. Plazzotta G. Veronica B. Bocchio-Chiavetto L. Riva M.A. Pariante C.M. Inflammation and neuronal plasticity: A link between childhood trauma and depression pathogenesis. Front. Cell. Neurosci. 2015 9 40 10.3389/fncel.2015.00040 25873859
139 Ficek J. Zygmunt M. Piechota M. Hoinkis D. Rodriguez Parkitna J. Przewlocki R. Korostynski M. Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. BMC Genomics 2016 17 1 362 10.1186/s12864-016-2713-3 27188165
